<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Initial management of high-risk gestational trophoblastic neoplasia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Initial management of high-risk gestational trophoblastic neoplasia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Initial management of high-risk gestational trophoblastic neoplasia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ross S Berkowitz, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Neil S Horowitz, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin M Elias, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara Goff, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Don S Dizon, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 06, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H19647741">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gestational trophoblastic disease (GTD) defines a group of conditions that arise from an aberrant fertilization event. When GTD recurs following surgical management, or when there is evidence of metastatic disease, it is called gestational trophoblastic neoplasia (GTN) and comprises four subtypes of disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Invasive mole
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Choriocarcinoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placental site trophoblastic tumor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epithelioid trophoblastic tumor
        </p>
        <p>
        </p>
        <p>
         The initial treatment of high-risk GTN is discussed here. The pathology, epidemiology, clinical manifestations, and staging of GTD are discussed separately. In addition, the management of low-risk and recurrent GTN are also discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3243.html" rel="external">
          "Hydatidiform mole: Epidemiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3230.html" rel="external">
          "Gestational trophoblastic disease: Pathology"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3194.html" rel="external">
          "Hydatidiform mole: Treatment and follow-up"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3242.html" rel="external">
          "Initial management of low-risk gestational trophoblastic neoplasia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19647747">
         <span class="h1">
          DEFINITION OF HIGH-RISK DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         High-risk invasive mole and choriocarcinoma are characterized by the International Federation of Gynecology and Obstetrics (FIGO) stage and the World Health Organization (WHO) Prognostic Scoring System (
         <a class="graphic graphic_table graphicRef98185" href="/z/d/graphic/98185.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/95881.html" rel="external">
          "Gestational trophoblastic neoplasia: Epidemiology, clinical features, diagnosis, staging, and risk stratification", section on 'Staging and risk assessment'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage IV disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stages II and III with risk score &gt;6
        </p>
        <p>
        </p>
        <p>
         While FIGO staging is also used for patients with placental site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT), the WHO risk scoring system is
         <strong>
          not
         </strong>
         used for such patients. Management of PSTT and ETT is also different than invasive mole and choriocarcinoma and is described below. (See
         <a class="local">
          'Metastatic PSTT or ETT'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H534180470">
         <span class="h1">
          APPROACH TO TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         GTN is uniquely sensitive to chemotherapy, which is the major
         <strong>
         </strong>
         treatment modality for patients with high-risk disease. The exception to this is women with placental site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT), which are relatively resistant to chemotherapy as compared with choriocarcinoma and invasive mole. As such, the primary treatment may be a combination of surgery and chemotherapy. Regardless, in the treatment of high-risk GTN, other modalities such as surgery and radiation therapy (RT) may be indicated in addition to chemotherapy.
        </p>
        <p>
         For patients in whom combination chemotherapy is indicated, treatment may result in ovarian insufficiency. Therefore, we advocate for the use of oral contraceptives or gonadotropin-releasing hormone agonists to suppress the pituitary glands' production of luteinizing hormone, which aims to protect the ovaries from the toxicity of chemotherapy and also suppress the pituitary production of human chorionic gonadotropin (hCG), which in our clinical experience, could falsely suggest the presence of active disease if not suppressed [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19647753">
         <span class="h2">
          Chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with high-risk GTN are likely to develop drug resistance if single-agent therapy is administered. Therefore, these patients are commonly treated with multi-agent regimens. Evidence of the greater likelihood of resistance to single-agent chemotherapy comes from early work at the National Cancer Institute where only 36 percent of patients with high-risk GTN achieved remission with single-agent treatment [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Our preferred regimen for these patients is
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (MTX), plus actinomycin D (ActD) alternating with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         (EMA-CO) because it results in complete response rates between 71 and 78 percent and long-term survival rates of 85 to 94 percent [
         <a href="#rid3">
          3-12
         </a>
         ]. However, a 2012 Cochrane review has found that regimens that incorporate etoposide and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         are effective options, though the lack of randomized trials prevented an analysis to define the optimal regimen [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19647766">
         <span class="h3">
          EMA-CO
         </span>
         <span class="headingEndMark">
          —
         </span>
         MTX, plus ActD, alternating with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         (EMA-CO) has emerged as the regimen of choice for initial treatment of high-risk GTN [
         <a href="#rid14">
          14
         </a>
         ]. This is predominantly based on retrospective data that consistently show it is active in high-risk GTN and is associated with a low toxicity profile (
         <a class="graphic graphic_table graphicRef98319" href="/z/d/graphic/98319.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid13">
          13,15
         </a>
         ].
        </p>
        <p>
         The components of this regimen are [
         <a href="#rid11">
          11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          Etoposide
         </a>
         – 100 mg/m
         <sup>
          2
         </sup>
         IV over 30 minutes on days 1 and 2
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MTX – 100 mg/m
         <sup>
          2
         </sup>
         IV bolus followed by 200 mg/m
         <sup>
          2
         </sup>
         IV over 12 hours on day 1
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ActD – 0.5 mg IV bolus on days 1 and 2
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          Leucovorin
         </a>
         calcium – 15 mg orally every 12 hours for four doses, starting 24 hours after start of MTX
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         – 600 mg/m
         <sup>
          2
         </sup>
         IV on day 8
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          Vincristine
         </a>
         – 1.0 mg/m
         <sup>
          2
         </sup>
         IV on day 8
        </p>
        <p>
        </p>
        <p>
         Although EMA-CO is the most widely used regimen, there have been no randomized trials to demonstrate that it should be the preferred regimen. However, compared with other combination regimens, it appears to be as effective (if not more so) and better tolerated.
        </p>
        <p>
         This was shown in one report that included over 200 women with high-risk GTN treated with a variety of multi-agent regimens [
         <a href="#rid15">
          15
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MTX plus ActD and folinic acid (MA, administered between 1971 and 1995)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MTX, ActD,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         ,
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         , and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         (CHAMOCA, administered between 1982 and 1995)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MTX, ActD, and
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         (MAC, administered between 1971 and 1982)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EMA-CO (administered between 1985 and 1995)
        </p>
        <p>
        </p>
        <p>
         Of these four regimens, EMA-CO resulted in [
         <a href="#rid15">
          15
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The highest remission rate (91 percent) compared with MA, CHAMOCA, and MAC (63, 76, and 68 percent, respectively) and required the fewest number of courses to attain remission
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The lowest mortality rate (9 percent versus 37, 22, and 33 percent, respectively)
        </p>
        <p>
        </p>
        <p>
         In a 2012 systematic review, the administration of EMA-CO was associated with primary remission rates ranging from 54 to 91 percent of patients [
         <a href="#rid13">
          13
         </a>
         ]. These data support the use of EMA-CO as a primary treatment for high-risk GTN.
        </p>
        <p class="headingAnchor" id="H534180600">
         <span class="h3">
          Administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment with EMA-CO should be administered every two to three weeks. Although a treatment delay or dose reduction may be required due to side effects, these should be avoided as both have been associated with less than optimal outcomes. We routinely employ growth factor support to help minimize hematologic toxicity and to help avoid delays [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Treatment should be continued until the hCG level becomes undetectable and remains undetectable for three consecutive weeks. Finally, we administer at least three courses of EMA-CO after the patient achieves undetectable hCG levels as consolidation therapy to reduce the risk of relapse, which is supported by the limited data. (See
         <a class="medical medical_review" href="/z/d/html/3242.html" rel="external">
          "Initial management of low-risk gestational trophoblastic neoplasia", section on 'Remission and consolidation treatment'
         </a>
         .)
        </p>
        <p>
         The Charing Cross Group has reported the use of induction low-dose
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         (100 mg/m
         <sup>
          2
         </sup>
         ) and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (20 mg/m
         <sup>
          2
         </sup>
         ) on days 1 and 2 every seven days in selected patients with high tumor burden. This has almost completely eliminated early mortality from respiratory compromise and hemorrhage. They also report a 94 percent remission rate with EMA-CO by carefully excluding non-gestational tumors using genetic analysis [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19647772">
         <span class="h3">
          Patients with brain metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with brain metastases, a neurosurgical consult should be obtained prior to treatment. These patients are at risk for complications directly related to their brain metastases or as a consequence of treatment, which may require urgent or emergent treatment (eg, craniotomy for intracerebral bleeding). For these patients, we administer a modification of systemic EMA-CO that uses a higher MTX dose (1000 mg/m
         <sup>
          2
         </sup>
         over 24 hours) than what is routinely administered [
         <a href="#rid18">
          18
         </a>
         ]. The higher dose of parenteral MTX allows for adequate levels of MTX within the cerebrospinal fluid (CSF) [
         <a href="#rid18">
          18-21
         </a>
         ]. In addition, these patients should receive
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         to decrease
         <strong>
          cerebral
         </strong>
         edema; however, prophylactic anti-epileptic drugs are generally not recommended in most patients, provided there is no history of an antecedent seizure. (See
         <a class="medical medical_review" href="/z/d/html/5181.html" rel="external">
          "Seizures in patients with primary and metastatic brain tumors"
         </a>
         .)
        </p>
        <p>
         A typical regimen is as follows [
         <a href="#rid21">
          21
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          Etoposide
         </a>
         – 100 mg/m
         <sup>
          2
         </sup>
         IV over 60 minutes on days 1 and 2
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MTX – 1000 mg/m
         <sup>
          2
         </sup>
         IV over 24 hours on day 1
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ActD – 0.5 mg IV bolus on days 1 and 2
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          Leucovorin
         </a>
         calcium – 30 mg intramuscular (IM) or orally every 12 hours for three days, starting 32 hours after treatment with MTX
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         – 600 mg/m
         <sup>
          2
         </sup>
         IV on day 8
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          Vincristine
         </a>
         – 1.0 mg/m
         <sup>
          2
         </sup>
         IV on day 8
        </p>
        <p>
         At these high doses of MTX, significant renal toxicity can occur, typically from crystallization of the MTX in the renal tubules. Renal dysfunction can lead to decreased MTX clearance, which leads to more significant nonrenal toxicities (eg, myelosuppression, mucositis, etc). Adequate hydration and alkalinization of the urine with
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         can help prevent these problems [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Finally, these patients should be closely followed during treatment, which can be done using serial imaging.
        </p>
        <p class="headingAnchor" id="H534180552">
         <span class="h4">
          Role for intrathecal therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The need for intrathecal (IT) therapy in these patients is controversial [
         <a href="#rid19">
          19,21,23,24
         </a>
         ], and its use alongside high-dose EMA-CO is based on institutional preferences. If administered, MTX is given as a 12.5 mg dose IT on day 8, followed by
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         calcium 15 mg at 24 and 36 hours. However, one study that included 15 patients treated with EMA-CO plus IT MTX reported that 87 percent (13 patients) achieved a sustained remission without the use of whole-brain irradiation [
         <a href="#rid21">
          21
         </a>
         ]. An update of this study reported that 23 (85 percent) of 27 patients with brain metastases achieved complete remission with EMA-CO or EMA-EP (
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         on day 8) plus IT MTX [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19647778">
         <span class="h4">
          Concomitant whole-brain radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         At the New England Trophoblastic Disease Center, we have administered cranial RT (20 to 30 Gy in 2 Gy daily fractions) concurrently with high-dose MTX chemotherapy. As with the role of IT MTX, the role of cranial RT is also controversial. In addition to shrinking the brain metastases, concomitant cranial irradiation increases the MTX concentration within the central nervous system (CNS) [
         <a href="#rid26">
          26
         </a>
         ] and reduces the risk of cerebral hemorrhage prior to eradication of tumor, and may improve survival [
         <a href="#rid27">
          27,28
         </a>
         ]. However, the use of concurrent MTX and cranial irradiation also increased the likelihood of treatment-related toxicity, especially leukoencephalopathy. (See
         <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">
          "Delayed complications of cranial irradiation", section on 'Neurocognitive effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19647796">
         <span class="h3">
          Cisplatin-containing regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         In many centers, a modified EMA-CO regimen that incorporates
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         is preferentially administered to patients with a risk score ≥12. The most commonly used combination replaces
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (used in EMA-CO) with
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         and cisplatin on day 8 (EMA-EP) (
         <a class="graphic graphic_table graphicRef98320" href="/z/d/graphic/98320.html" rel="external">
          table 3
         </a>
         ). EMA-EP alone or in combination with surgery induced complete remission in 16 (76 percent) of 21 patients with EMA-CO resistance [
         <a href="#rid5">
          5
         </a>
         ]. Among 143 patients with ultra-high-risk GTN (International Federation of Gynecology and Obstetrics [FIGO] score ≥12), only 97 (67.9 percent) achieved complete remission [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         While no randomized trials compared EMA-CO with cisplatin-containing regimens, a retrospective study evaluated outcomes among 83 patients treated with cisplatin-containing treatment and 103 patients treated with EMA-CO [
         <a href="#rid30">
          30
         </a>
         ]. Compared with EMA-CO, incorporation of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         was associated with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A slightly lower remission rate (85 versus 92 percent, respectively)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A lower number of cycles to achieve a normal hCG level (three versus five courses)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More toxicity, including fever, nephropathy, nausea, and diarrhea
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2699263725">
         <span class="h2">
          FAEV
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment with
         <a class="drug drug_general" data-topicid="8942" href="/z/d/drug information/8942.html" rel="external">
          floxuridine
         </a>
         , ActD,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         (FAEV) has also been reported. In one study of 30 patients with stage IV GTN receiving primary treatment with FAEV, 24 (80 percent) patients achieved complete and sustained remission with tolerable toxicity [
         <a href="#rid31">
          31
         </a>
         ]. Among six patients with resistance, two died from progressive disease and four achieved remission with other regimens.
        </p>
        <p>
         A review of 17 studies summarizing responses to EMA-CO, EMA-EP, and FAEV in the first-line setting for ultra-high-risk GTN concluded all three regimens had similar complete response rates [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H57680584">
         <span class="h3">
          APE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the activity of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         for GTN, one group reported their experience using ActD, cisplatin, and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         (APE) for high-risk GTN that included 59 patients (out of a total of 95) who were treated with this regimen as initial therapy between 1985 and 2013 [
         <a href="#rid33">
          33
         </a>
         ]. Patients with brain metastases or PSTT were excluded from treatment. The overall remission rate for these patients was 95 percent. One patient required treatment discontinuation after four cycles due to grade 2 ototoxicity. The final two had refractory disease to this regimen, but all three entered remission with second-line EMA-CO therapy. The five-year disease-free survival rate was 98 percent.
        </p>
        <p class="headingAnchor" id="H534180702">
         <span class="h2">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 50 percent of patients with high-risk, metastatic GTN will require adjuvant surgery to achieve cure, even in the presence of multi-organ involvement [
         <a href="#rid34">
          34-47
         </a>
         ]. As an example, in one study of 50 patients with high-risk, metastatic GTN treated with EMA-CO between 1986 and 2005, among 24 patients who underwent a total of 28 surgical procedures, the cure rate was 87.5 percent. These procedures included hysterectomy, pulmonary resection, uterine wedge resection, small bowel resection, and selective uterine artery embolization [
         <a href="#rid40">
          40
         </a>
         ]. Surgery is generally performed to resect foci of chemotherapy-resistant disease or to control complications such as bleeding or infection.
        </p>
        <p class="headingAnchor" id="H473164634">
         <span class="h1">
          METASTATIC PSTT OR ETT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although universally accepted guidelines are not available, patients with metastatic placental site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT) should be treated with a combination of surgery and chemotherapy. Multi-agent regimens are usually administered, including
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , plus actinomycin D alternating with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         (EMA-CO) [
         <a href="#rid48">
          48
         </a>
         ] or EMA plus etoposide and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (EMA-EP) [
         <a href="#rid49">
          49
         </a>
         ]. There are no prospective data to inform whether one or the other is the preferred regimen. In a retrospective review of cases of 37 women with stage II to IV PSTT treated with floxuridine-based regimens, the initial response rate was 92 percent, with a 20.6 percent relapse rate. Hysterectomy was performed in 28 (78.4 percent) of the patients [
         <a href="#rid50">
          50
         </a>
         ]. While data are more limited, it appears that ETT is even less responsive to chemotherapy than PSTT [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/96235.html" rel="external">
          "Management of resistant or recurrent gestational trophoblastic neoplasia", section on 'High-risk GTN'
         </a>
         .)
        </p>
        <p>
         Unfortunately, patients with metastatic disease have a relatively poor prognosis and a high fatality rate [
         <a href="#rid52">
          52-54
         </a>
         ]. In a 2012 review of the literature that reported on the deaths from GTN, 30 percent had PSTT [
         <a href="#rid54">
          54
         </a>
         ]. In addition, one single-institution series of 18 patients with PSTT reported that five of six who had extrauterine disease ultimately died despite the administration of multi-agent chemotherapy [
         <a href="#rid53">
          53
         </a>
         ]. Survival with PSTT is strongly related to the number of years since the antecedent pregnancy. Papadopoulos et al, reporting on 34 patients, found that while all 27 patients diagnosed within four years of the antecedent pregnancy survived, all seven patients died when the antecedent pregnancy was more than four years [
         <a href="#rid52">
          52
         </a>
         ]. Among 16 patients with stage II to IV ETT, chemotherapy and surgery in 10 patients achieved remission at 1 year in 8 (80 percent) patients [
         <a href="#rid55">
          55
         </a>
         ]. Survival was adversely affected if the interval from the antecedent pregnancy was greater than four years.
        </p>
        <p>
         As a result of this very poor prognosis, some have advocated the use of high-dose chemotherapy with peripheral blood stem cell support. In an observational study, this aggressive therapy achieved a 45 percent remission rate. Survivors tended to have a low human chorionic gonadotropin (≤12 international units/L) at the time of treatment initiation [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         In an update to a series including 125 patients with PSTT or ETT, the overall probability of survival at 5 and 10 years following treatment was 80 and 75 percent, respectively [
         <a href="#rid57">
          57
         </a>
         ]. Stage IV disease (hazard ratio [HR] 6.2) and a time interval ≥48 months since the antecedent pregnancy (HR 14.6) remained the significant prognostic factors for death on multivariable analysis. However, with the introduction of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         regimens and high-dose chemotherapy with stem cell support, patients with an interval ≥48 months demonstrated an improved median overall survival compared with the prior report (8.3 versus 2.6 years).
        </p>
        <p class="headingAnchor" id="H19647814">
         <span class="h1">
          MONITORING DURING TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with women who are treated for low-risk GTN, all women with high-risk GTN should be monitored with serial measurements of serum human chorionic gonadotropin (hCG) at the start of treatment and then at weekly intervals during therapy. This and other considerations for patients during treatment are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3242.html" rel="external">
          "Initial management of low-risk gestational trophoblastic neoplasia", section on 'Monitoring during treatment'
         </a>
         .)
        </p>
        <p>
         The approximate biologic half-life of hCG is 1.5 to 3 days, and serum levels should fall exponentially (by at least one log within 18 days). A slower rate of decline suggests the possibility of chemoresistance, although there is no consensus or clear guideline as to the optimal cutoff for determining chemoresistance or the management of patients with a slower than expected tumor marker decline [
         <a href="#rid58">
          58-60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19647820">
         <span class="h2">
          Definition of remission
         </span>
         <span class="headingEndMark">
          —
         </span>
         Remission is achieved when the quantitative hCG level becomes undetectable for three consecutive weeks. Given the sensitivity of this tumor marker, no imaging is required if levels are consistent with remission because abnormalities on imaging can persist despite the attainment of undetectable hCG levels, representing fibrosis rather than active tumor.
        </p>
        <p class="headingAnchor" id="H19647826">
         <span class="h2">
          Persistent or progressive disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The French Trophoblastic Disease Reference Center in Lyon defines chemotherapy resistance as an increase or a plateau in two consecutive hCG values over a two-week interval [
         <a href="#rid61">
          61
         </a>
         ]. As described above, other generally accepted criteria include detection of new metastases [
         <a href="#rid62">
          62
         </a>
         ]. For patients who appear to have persistent disease, surgery may be a curative option. The approach to patients who experience disease progression is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/96235.html" rel="external">
          "Management of resistant or recurrent gestational trophoblastic neoplasia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19647832">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall cure rate for patients with high-risk GTN (stage II to III) ranges between 90 and 100 percent [
         <a href="#rid63">
          63
         </a>
         ]. At the New England Trophoblastic Disease Center (NETDC), we treated 93 patients between July 1965 and December 2018, of whom 75 percent had a sustained complete remission with primary chemotherapy (
         <a class="graphic graphic_table graphicRef98248" href="/z/d/graphic/98248.html" rel="external">
          table 4
         </a>
         ). As depicted in the table, of those who developed resistance, second-line therapy ultimately resulted in sustained remission in 85 percent of patients. Overall, 90 (97 percent) of 93 patients with high-risk stage II and III GTN achieved complete remission.
        </p>
        <p>
         For patients with International Federation of Gynecology and Obstetrics (FIGO) stage IV high-risk GTN, the prognosis is not as good, though complete remission can be expected in 60 to 70 percent of patients [
         <a href="#rid63">
          63
         </a>
         ]. Much of this success is due to the use of combination chemotherapy. After combination chemotherapy was introduced as primary treatment in this group, the survival rate dramatically improved. Since the introduction of intensive primary combination chemotherapy with adjunctive surgery and radiation therapy, survival at the NETDC increased from 30 to 78 percent (
         <a class="graphic graphic_table graphicRef98252" href="/z/d/graphic/98252.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19647839">
         <span class="h2">
          Prognostic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with high-risk GTN, long-term survival appears to be associated with variables related to disease extent [
         <a href="#rid64">
          64
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the presence of liver metastases, only 27 percent were alive
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If brain metastases were present, the survival rate was 70 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If both were present, only 10 percent were alive
        </p>
        <p>
        </p>
        <p>
         Data from the Charing Cross Hospital indicate that survival with hepatic metastases appears to have improved over time. Excluding early deaths (within four weeks of presentation) and two deaths unrelated to GTN, the cause-specific survival in 25 patients was 68 percent [
         <a href="#rid65">
          65,66
         </a>
         ].
        </p>
        <p>
         Other poor prognostic factors have also been reported. A retrospective study including 10 GTN Reference Centers in Brazil confirmed the negative prognostic impact of brain and liver metastases, but also identified additional risk factors for death from high-risk GTN including increased time between the end of antecedent pregnancy and the initiation of chemotherapy (relative risk [RR] 4.1), chemoresistance (RR 3.2), and initial treatment outside the Reference Center (RR 28.3) [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19647845">
         <span class="h1">
          POST-TREATMENT SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         After remission is achieved, serum human chorionic gonadotropin (hCG) should be measured monthly until there have been undetectable hCG levels for 12 months [
         <a href="#rid68">
          68,69
         </a>
         ]. In a population-based cohort study from the United Kingdom, 86 percent of recurrences in patients with high-risk GTN occurred within one year of treatment cessation and 95 percent occurred within two years [
         <a href="#rid70">
          70
         </a>
         ]. These data support discontinuing routine monitoring after one year. If a patient develops a rising hCG after remission, it is important to consider alternative sources for this elevation. These would include a new conception, which could be new molar pregnancy or a new intrauterine pregnancy, or pituitary hCG, which is more common if the ovaries experience significant damage following intensive combination chemotherapy [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         Assays should measure hCG at least down to 5 milli-international units/mL and should measure not only intact hCG but also hCG fragments and subunits. When assays measure hCG to very low levels (&lt;1 milli-international units/mL), it is particularly important to suppress pituitary production of luteinizing hormone and hCG with strong, oral contraceptives to facilitate reliable monitoring of disease status. (See
         <a class="medical medical_review" href="/z/d/html/3209.html" rel="external">
          "Human chorionic gonadotropin: Biochemistry and measurement in pregnancy and disease"
         </a>
         .)
        </p>
        <p>
         The follow-up of patients treated for high-risk GTN is similar to that of women treated for low-risk GTN and includes considerations of contraception and the timing of subsequent pregnancies. These issues are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3242.html" rel="external">
          "Initial management of low-risk gestational trophoblastic neoplasia", section on 'Posttreatment surveillance'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3242.html" rel="external">
          "Initial management of low-risk gestational trophoblastic neoplasia", section on 'Posttreatment issues'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H534181291">
         <span class="h2">
          Uterine arteriovenous malformation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients treated for GTN that invaded the myometrium (both low-risk and high-risk) are at risk of developing a uterine artery malformation (also known as an arteriovenous fistula), which can persist for months or years after remission is achieved. A fistula may remain asymptomatic and undiagnosed or may present with menorrhagia. The presence of an arteriovenous malformation has also been associated with recurrent miscarriage.
        </p>
        <p>
         The diagnosis is made with the use of color Doppler transabdominal or endovaginal ultrasonography.
         <strong>
         </strong>
         Selective pelvic arteriography clearly identifies the abnormal vascular malformation and helps in evaluating possible treatment modalities. If symptomatic, treatment consists of hysterectomy or, when preservation of reproductive function is desired, treatment consists of selective uterine artery embolization [
         <a href="#rid72">
          72-74
         </a>
         ]. When uterine artery embolization is not available, treatment with
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         and
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         controlled hemorrhage in 14 of 16 (87.5 percent) patients with class I to II hemorrhage and in 6 of 11 (54.5 percent) patients with class III to IV hemorrhage (American College of Surgeons Classification of Hemorrhage) [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19647851">
         <span class="h1">
          DIAGNOSIS OF RECURRENT OR RESISTANT DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients whose human chorionic gonadotropin (hCG) level re-elevates after becoming undetectable for three consecutive weeks are considered to have
         <strong>
          recurrent
         </strong>
         disease. By contrast, patients whose hCG level remains elevated despite treatment are considered to have
         <strong>
          resistant
         </strong>
         disease. Despite the success of combination chemotherapy, patients treated for high-risk GTN have an 8 to 10 percent risk of recurrence, dependent on stage and risk score [
         <a href="#rid76">
          76
         </a>
         ]. This is often detected by a re-elevation in the quantitative serum hCG levels after three consecutive weeks of undetectable quantitative hCG levels. The approach to patients with recurrent or resistant disease is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/96235.html" rel="external">
          "Management of resistant or recurrent gestational trophoblastic neoplasia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3940777292">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120644.html" rel="external">
          "Society guideline links: Gestational trophoblastic disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H534181297">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gestational trophoblastic neoplasia (GTN) is characterized by the International Federation of Gynecology and Obstetrics (FIGO) stage and the World Health Organization (WHO) risk score (
         <a class="graphic graphic_table graphicRef98185" href="/z/d/graphic/98185.html" rel="external">
          table 1
         </a>
         ). Patients are defined as having high-risk GTN if they have stage IV disease or stage II to III disease with a risk score &gt;6. (See
         <a class="local">
          'Definition of high-risk disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The WHO Prognostic Scoring System is not applicable to patients with placental site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT). Therefore, patients with these subtypes of GTN are not categorized as either low risk or high risk. They should be characterized by their FIGO stage. (See
         <a class="local">
          'Definition of high-risk disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         GTN is uniquely sensitive to chemotherapy, which is the major treatment modality for patients with high-risk disease. The exception to this is women with PSTT or ETT, in which case, the primary treatment may be a combination of surgery and chemotherapy, primarily because PSTT and ETT are relatively resistant to chemotherapy as compared with choriocarcinoma and invasive mole. (See
         <a class="local">
          'Approach to treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with high-risk GTN, we recommend multi-agent chemotherapy rather than single-agent therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). We suggest a combination of
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (MTX), plus actinomycin D (ActD) alternating with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         (EMA-CO) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'EMA-CO'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with high-risk GTN and brain metastases, a neurosurgical consult should be obtained prior to treatment. We suggest EMA-CO as the primary systemic treatment, using a higher MTX dose (1000 mg/m
         <sup>
          2
         </sup>
         over 24 hours) than what is routinely administered otherwise (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We also suggest cranial radiation therapy (RT) for these patients (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, for patients who do not wish to proceed with cranial RT, we suggest additional chemotherapy using intrathecal MTX (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Patients with brain metastases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Approximately 50 percent of patients with high-risk, metastatic GTN will require adjuvant surgery to achieve cure, even in the presence of multi-organ involvement. (See
         <a class="local">
          'Surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although universally accepted guidelines are not available, for patients with PSTT or ETT, we suggest a combination of surgery and chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Multi-agent regimens are usually administered, including EMA-CO or EMA plus
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (EMA-EP). There are no prospective data to inform whether one or the other is the preferred regimen, and a choice between them is based on institutional preferences. (See
         <a class="local">
          'Metastatic PSTT or ETT'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As with women who are treated for low-risk GTN, all women with high-risk GTN should be monitored with serial measurements of serum human chorionic gonadotropin (hCG) at the start of treatment and then at weekly intervals during therapy. (See
         <a class="local">
          'Monitoring during treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The overall cure rate for patients with high-risk GTN (stage II to III) ranges between 95 and 100 percent. The extent of disease is a prognostic factor among these patients. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After remission is achieved, serum hCG should be measured monthly until monitoring has shown one year of normal hCG levels. (See
         <a class="local">
          'Post-treatment surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2061207898">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Donald Peter Goldstein, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Cole LA, Sasaki Y, Muller CY. Normal production of human chorionic gonadotropin in menopause. N Engl J Med 2007; 356:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ROSS GT, GOLDSTEIN DP, HERTZ R, et al. SEQUENTIAL USE OF METHOTREXATE AND ACTINOMYCIN D IN THE TREATMENT OF METASTATIC CHORIOCARCINOMA AND RELATED TROPHOBLASTIC DISEASES IN WOMEN. Am J Obstet Gynecol 1965; 93:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schink JC, Singh DK, Rademaker AW, et al. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. Obstet Gynecol 1992; 80:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolis G, Bonazzi C, Landoni F, et al. EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). Gynecol Oncol 1988; 31:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bower M, Newlands ES, Holden L, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997; 15:2636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SJ, Bae SN, Kim JH, et al. Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen. Gynecol Oncol 1998; 71:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsui H, Suzuka K, Iitsuka Y, et al. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol Oncol 2000; 78:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escobar PF, Lurain JR, Singh DK, et al. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol 2003; 91:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turan T, Karacay O, Tulunay G, et al. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int J Gynecol Cancer 2006; 16:1432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cagayan MS. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. J Reprod Med 2012; 57:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med 2006; 51:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maestá I, de Freitas Segalla Moreira M, Rezende-Filho J, et al. Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America. Int J Gynecol Cancer 2020; 30:1366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deng L, Zhang J, Wu T, Lawrie TA. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev 2013; :CD005196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horowitz NS, Eskander RN, Adelman MR, Burke W. Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation. Gynecol Oncol 2021; 163:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SJ, Bae SN, Kim JH, et al. Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT--25 years experiences of KRI-TRD. Int J Gynaecol Obstet 1998; 60 Suppl 1:S85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanis MJ, Sobecki-Rausch J, Greendyk R, et al. Use of granulocyte colony stimulating facors (G-CSFs) with multiagent chemotherapy for gestational trophoblastic neoplasia (GTN). Gynecol Oncol 2017; 145S: SGO #474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alifrangis C, Agarwal R, Short D, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 2013; 31:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newlands ES, Holden L, Seckl MJ, et al. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med 2002; 47:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newlands ES. The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN). Best Pract Res Clin Obstet Gynaecol 2003; 17:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Small W Jr, Lurain JR, Shetty RM, et al. Gestational trophoblastic disease metastatic to the brain. Radiology 1996; 200:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rustin GJ, Newlands ES, Begent RH, et al. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 1989; 7:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard SC, McCormick J, Pui CH, et al. Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist 2016; 21:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakri Y, Berkowitz RS, Goldstein DP, et al. Brain metastases of gestational trophoblastic tumor. J Reprod Med 1994; 39:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altintaş A, Vardar MA. Central nervous system involvement in gestational trophoblastic neoplasia. Eur J Gynaecol Oncol 2001; 22:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage P, Kelpanides I, Tuthill M, et al. Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome. Gynecol Oncol 2015; 137:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrington S. Enhancing cure and palliation: radiation therapy in the treatment of metastatic gestational trophoblastic neoplasia. Semin Oncol 1995; 22:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yordan EL Jr, Schlaerth J, Gaddis O, Morrow CP. Radiation therapy in the management of gestational choriocarcinoma metastatic to the central nervous system. Obstet Gynecol 1987; 69:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Athanassiou A, Begent RH, Newlands ES, et al. Central nervous system metastases of choriocarcinoma. 23 years' experience at Charing Cross Hospital. Cancer 1983; 52:1728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kong Y, Yang J, Jiang F, et al. Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: A retrospective cohort study. Gynecol Oncol 2017; 146:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lybol C, Thomas CM, Blanken EA, et al. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Eur J Cancer 2013; 49:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang J, Xiang Y, Wan X, et al. Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): A report based on our 10-year clinical experiences. Gynecol Oncol 2016; 143:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Yue H, Wang X, et al. Chemotherapy for gestational trophoblastic neoplasia patients with a FIGO score of 12 or greater: A multistudy analysis. Eur J Obstet Gynecol Reprod Biol 2019; 238:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Even C, Pautier P, Duvillard P, et al. Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia. Eur J Cancer 2014; 50:2082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009; 112:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomoda Y, Arii Y, Kaseki S, et al. Surgical indications for resection in pulmonary metastasis of choriocarcinoma. Cancer 1980; 46:2723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming EL, Garrett L, Growdon WB, et al. The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2008; 53:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones WB, Romain K, Erlandson RA, et al. Thoracotomy in the management of gestational choriocarcinoma. A clinicopathologic study. Cancer 1993; 72:2175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoekstra AV, Lurain JR, Rademaker AW, Schink JC. Gestational trophoblastic neoplasia: treatment outcomes. Obstet Gynecol 2008; 112:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alazzam M, Hancock BW, Tidy J. Role of hysterectomy in managing persistent gestational trophoblastic disease. J Reprod Med 2008; 53:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lurain JR, Singh DK, Schink JC. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 2006; 51:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pisal N, North C, Tidy J, Hancock B. Role of hysterectomy in management of gestational trophoblastic disease. Gynecol Oncol 2002; 87:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu LT, Sun CF, Wang YE, Song HZ. Resection of pulmonary metastatic choriocarcinoma in 43 drug-resistant patients. Ann Thorac Surg 1985; 39:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang YA, Song HZ, Xia ZF, Sun CF. Drug resistant pulmonary choriocarcinoma metastasis treated by lobectomy: report of 29 cases. Chin Med J (Engl) 1980; 93:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cagayan MS, Magallanes MS. The role of adjuvant surgery in the management of gestational trophoblastic neoplasia. J Reprod Med 2008; 53:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soper JT. Role of surgery and radiation therapy in the management of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol 2003; 17:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark RM, Nevadunsky NS, Ghosh S, et al. The evolving role of hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2010; 55:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eysbouts YK, Massuger LFAG, IntHout J, et al. The added value of hysterectomy in the management of gestational trophoblastic neoplasia. Gynecol Oncol 2017; 145:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newlands ES, Mulholland PJ, Holden L, et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 2000; 18:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newlands ES, Bower M, Fisher RA, Paradinas FJ. Management of placental site trophoblastic tumors. J Reprod Med 1998; 43:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao J, Lv WG, Feng FZ, et al. Placental site trophoblastic tumor: A review of 108 cases and their implications for prognosis and treatment. Gynecol Oncol 2016; 142:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis MR, Howitt BE, Quade BJ, et al. Epithelioid trophoblastic tumor: A single institution case series at the New England Trophoblastic Disease Center. Gynecol Oncol 2015; 137:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papadopoulos AJ, Foskett M, Seckl MJ, et al. Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med 2002; 47:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyman DM, Bakios L, Gualtiere G, et al. Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome. Gynecol Oncol 2013; 129:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kingdon SJ, Coleman RE, Ellis L, Hancock BW. Deaths from gestational trophoblastic neoplasia: any lessons to be learned? J Reprod Med 2012; 57:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frijstein MM, Lok CAR, van Trommel NE, et al. Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database. Gynecol Oncol 2019; 152:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frijstein MM, Lok CAR, Short D, et al. The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia. Eur J Cancer 2019; 109:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Froeling FEM, Ramaswami R, Papanastasopoulos P, et al. Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours. Br J Cancer 2019; 120:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Trommel NE, Massuger LF, Schijf CP, et al. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol 2006; 24:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           You B, Pollet-Villard M, Fronton L, et al. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol 2010; 21:1643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerkmeijer LG, Thomas CM, Harvey R, et al. External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. Br J Cancer 2009; 100:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golfier F, Labrousse C, Frappart L, et al. [Evaluation of treatment relating to gestational trophoblastic tumor registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon from 1999 to 2005]. Gynecol Obstet Fertil 2007; 35:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeish IA, Strickland S, Holden L, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002; 20:1838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol 2011; 204:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lurain JR, Schink JC. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 2012; 57:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010; 376:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahamed E, Short D, North B, et al. Survival of women with gestational trophoblastic neoplasia and liver metastases: is it improving? J Reprod Med 2012; 57:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freitas F, Braga A, Viggiano M, et al. Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. Gynecol Oncol 2020; 158:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Practice Bulletins-Gynecology, American College of Obstetricians and Gynecologists. ACOG Practice Bulletin #53. Diagnosis and treatment of gestational trophoblastic disease. Obstet Gynecol 2004; 103:1365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society of Gynecologic Oncologists Clinical Practice Guidelines. Practice guidelines: gestational trophoblastic disease. Oncology (Williston Park) 1998; 12:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balachandran K, Salawu A, Ghorani E, et al. When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): A national analysis on over 4,000 patients. Gynecol Oncol 2019; 155:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elias KM, Berkowitz RS, Horowitz NS. Continued hCG surveillance following chemotherapy for gestational trophoblastic neoplasia: When is enough enough? Gynecol Oncol 2019; 155:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim AK, Agarwal R, Seckl MJ, et al. Embolization of bleeding residual uterine vascular malformations in patients with treated gestational trophoblastic tumors. Radiology 2002; 222:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang JJ, Xiang Y, Wan XR, Yang XY. Diagnosis and management of uterine arteriovenous fistulas with massive vaginal bleeding. Int J Gynaecol Obstet 2005; 89:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGrath S, Harding V, Lim AK, et al. Embolization of uterine arteriovenous malformations in patients with gestational trophoblastic tumors: a review of patients at Charing Cross Hospital, 2000-2009. J Reprod Med 2012; 57:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braga A, Lima L, Parente RCM, et al. Management of symptomatic uterine arterial malformation after gestational trophoblastic disease:  The Brazilian experience and possible role for depot medroxyprogesterone acetate and tranexamic acid treatment. J Reprod Med 2018; 63:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein DP, Zanten-Przybysz IV, Bernstein MR, Berkowitz RS. Revised FIGO staging system for gestational trophoblastic tumors. Recommendations regarding therapy. J Reprod Med 1998; 43:37.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 96232 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17361004" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Normal production of human chorionic gonadotropin in menopause.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14336651" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : SEQUENTIAL USE OF METHOTREXATE AND ACTINOMYCIN D IN THE TREATMENT OF METASTATIC CHORIOCARCINOMA AND RELATED TROPHOBLASTIC DISEASES IN WOMEN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1328977" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2846414" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9215835" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9826467" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10873405" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14675675" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16803542" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22696818" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17086804" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32376739" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23440800" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34686354" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9833620" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT--25 years experiences of KRI-TRD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Use of granulocyte colony stimulating facors (G-CSFs) with multiagent chemotherapy for gestational trophoblastic neoplasia (GTN)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23233709" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12092015" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Management of brain metastases in patients with high-risk gestational trophoblastic tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14614889" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8657926" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Gestational trophoblastic disease metastatic to the brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2472471" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27496039" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Preventing and Managing Toxicities of High-Dose Methotrexate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7518516" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Brain metastases of gestational trophoblastic tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11446484" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Central nervous system involvement in gestational trophoblastic neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25598530" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7537894" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Enhancing cure and palliation: radiation therapy in the treatment of metastatic gestational trophoblastic neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3822306" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Radiation therapy in the management of gestational choriocarcinoma metastatic to the central nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6684500" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Central nervous system metastases of choriocarcinoma. 23 years' experience at Charing Cross Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28461032" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: A retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23099004" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27426306" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): A report based on our 10-year clinical experiences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31136884" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Chemotherapy for gestational trophoblastic neoplasia patients with a FIGO score of 12 or greater: A multistudy analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24910417" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18851873" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Current management of gestational trophoblastic diseases
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7192596" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Surgical indications for resection in pulmonary metastasis of choriocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18720924" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8374875" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Thoracotomy in the management of gestational choriocarcinoma. A clinicopathologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18669719" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Gestational trophoblastic neoplasia: treatment outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18720927" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Role of hysterectomy in managing persistent gestational trophoblastic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17086805" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Role of surgery in the management of high-risk gestational trophoblastic neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12477450" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Role of hysterectomy in management of gestational trophoblastic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4038869" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Resection of pulmonary metastatic choriocarcinoma in 43 drug-resistant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6775886" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Drug resistant pulmonary choriocarcinoma metastasis treated by lobectomy: report of 29 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18720926" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The role of adjuvant surgery in the management of gestational trophoblastic neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14614891" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Role of surgery and radiation therapy in the management of gestational trophoblastic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20626174" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The evolving role of hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28390821" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The added value of hysterectomy in the management of gestational trophoblastic neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10673528" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9475150" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Management of placental site trophoblastic tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27168005" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Placental site trophoblastic tumor: A review of 108 cases and their implications for prognosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25773203" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Epithelioid trophoblastic tumor: A single institution case series at the New England Trophoblastic Disease Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12092014" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Twenty-five years' clinical experience with placental site trophoblastic tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23274560" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22838243" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Deaths from gestational trophoblastic neoplasia: any lessons to be learned?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30473257" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30731277" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30792530" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16382113" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20154304" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19293810" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17336125" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : [Evaluation of treatment relating to gestational trophoblastic tumor registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon from 1999 to 2005].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11919242" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20739008" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22696816" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20673583" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Gestational trophoblastic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22696824" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Survival of women with gestational trophoblastic neoplasia and liver metastases: is it improving?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32402634" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15172880" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : ACOG Practice Bulletin #53. Diagnosis and treatment of gestational trophoblastic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9534195" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Society of Gynecologic Oncologists Clinical Practice Guidelines. Practice guidelines: gestational trophoblastic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31375268" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): A national analysis on over 4,000 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31601360" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Continued hCG surveillance following chemotherapy for gestational trophoblastic neoplasia: When is enough enough?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11867779" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Embolization of bleeding residual uterine vascular malformations in patients with treated gestational trophoblastic tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15847873" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Diagnosis and management of uterine arteriovenous fistulas with massive vaginal bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22838248" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Embolization of uterine arteriovenous malformations in patients with gestational trophoblastic tumors: a review of patients at Charing Cross Hospital, 2000-2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Management of symptomatic uterine arterial malformation after gestational trophoblastic disease:  The Brazilian experience and possible role for depot medroxyprogesterone acetate and tranexamic acid treatment
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9475148" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Revised FIGO staging system for gestational trophoblastic tumors. Recommendations regarding therapy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
